Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The effects of vitamin D on acute viral respiratory infections: A rapid review

Ryan Bradleya,b,c,d,1, Janet Schlossc,d,1, Danielle Brownc, Deisy Celisb, John Finnellé,f, Rita Hedo1, Vladyslav Honcharovb, Traci Pantusof, Hilda Peñab, Romy Lauchec,d, Amie Steelc

a Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States
b University of California, San Diego, La Jolla, California, United States
c Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, New South Wales, Australia
d National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia
e South Texas Veterans Healthcare System, San Antonio, Texas, United States
f Bastyr University, Kenmore, Washington, United States

ARTICLE INFO

Article history:
Available online 3 August 2020

Keywords:
Vitamin D
Acute respiratory tract infection
Rapid review

ABSTRACT

Brief overview: Current evidence suggests vitamin D replacement may reduce risk for acute respiratory tract infections (ARTI) in people with deficiency or insufficiency, although the effects of supplementation on incidence and severity of ARTI in the general population remain unknown. Oral vitamin D supplementation taken at routine doses appears to be generally safe and well tolerated.

Verdict: Current experimental evidence remains inconclusive regarding the effects of vitamin D supplementation in the general population for the prevention and treatment of acute respiratory tract infections (ARTI). There is also insufficient evidence to draw conclusions regarding the impact of vitamin D supplementation on the severity or duration of ARTI, nor on outcomes related to lung injury or hospitalization from ARTI. Based on this rapid review, sources of significant heterogeneity in published clinical trials include: differences study populations, inconsistent assessment of serum status at baseline, dosing variability, varying routes of administration, and/or inconsistent definitions of outcome measures. Experimental evidence and observations in large cohorts are generally consistent that vitamin D deficiency (<50 nmol/L [<20 ng/mL]) and insufficiency (<75 nmol/L [<30 ng/mL]) of serum 25-hydroxycholecalciferol (25-OHD) concentration is associated with increased risk of ARTI, and supplementation for those with deficiency/insufficiency may lead to clinically meaningful reductions in the incidence of ARTI. In this rapid review, vitamin D was primarily administered as oral supplementation, and findings suggested significant differences in daily oral dosing compared to periodic bolus dosing. Based on the available experimental evidence, vitamin D supplementation appears to have a high margin of safety with very few adverse events reported in children or adults from a variety of dosing strategies. Future clinical trials on vitamin D should consider the sources of heterogeneity in the existing experimental research and design trials that account for baseline status, evaluate the potential for prevention and treatment in at risk populations, standardize dosing strategies, assess product quality, assess outcomes according to gold standard definitions/diagnostic methods, and delineate viral ARTI from other causes when possible. The available mechanistic evidence related to immunological requirements for adequate vitamin D, the availability of observational and experimental evidence suggestive of clinically meaningful benefits (especially in deficient/insufficient participants), and the high margin of safety, should make vitamin D a high priority for additional clinical research during the current COVID-19 pandemic.

© 2020 Published by Elsevier Ltd.

1. Background

Vitamin D, is a fat-soluble, secosteroidal hormone available to humans in the diet, nutritional supplements, and via direct production in the skin upon exposure to adequate ultraviolet light.
Dietary forms of vitamin D include cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2). Vitamin D is most commonly measured in serum as 25-OHD (calcidiol), as reported in this review, and less frequently as the more metabolically active form of 1,25-dihydroxycholecalciferol (calcitriol). Vitamin D has numerous fundamental functions in the innate and acquired immune response. Activation of both T- and B- cells leads to upregulation of the vitamin D receptor (VDR), allowing for changes in expression of over 500 vitamin D related genes [1–3]. Select mechanistic effects of Vitamin D on immune function include: enhancement of chemotaxis and phagocytosis [4], regulation of antibody production in B cells [5], inhibition of interleukin (IL)–2, interferon (IFN)–gamma, tumor necrosis factor (TNF)-alpha IL-9, and IL-22 [6–10], and increased IL-3, IL-4, IL-5, and IL-10 [11]. Observational research in the British Birth cohort has demonstrated significant linear relationships between serum 25-OHD concentration and lower risk of acute respiratory tract infection (ARTI), with each 10 nmol/L increase associated with a 7 % lower risk [12]. Further observational research in the United States (US)-based National Health and Nutrition Examination Survey (NHANES) 2001–2006 suggested those with insufficient serum status (25-OHD < 75 nmol/L) had 58% higher adjusted odds of ARTI [13]. Based on the numerous roles of vitamin D in the regulation of immune function, and notable observational research suggesting potential effects of ARTI, numerous randomized controlled trials in adults and children have aimed to learn the direct effects of vitamin D on risk of ARTI and their potential complications. The purpose of this rapid review is to summarize available systematic reviews of randomized, controlled clinical trials of vitamin D on ARTI and related outcomes.

2. Search strategy

2.1. Research question

What are the effects of Vitamin D on acute respiratory tract infections (ARTI) and associated complications?

2.2. Inclusion/exclusion criteria

Reviews were included if they were described as “systematic” and exhibited methods consistent with systematic reviews (i.e., defined clinical question, detailed search protocol, etc.) and reported on human prospective intervention trials sampling adults and/or children with reported ARTI. Reviews were excluded if they were designed as narrative reviews, non-review manuscripts, included only observational studies, and/or the study sample was not reported as diagnosed with ARTI.

2.3. Databases

Medline (OVID), Embase (OVID), AMED (OVID), and CINAHL

2.4. Search terms (example)

Five search strategies were pursued and compiled as follows: #1: exp Coronavirus Infections/ or exp Coronavirus/ or exp Coronaviridae/ or Influenza, Human/ or Influenza A Virus, H1N1 Subtype/ or Influenza A virus/ or Influenza A virus, H3N2 Subtype/ or Middle East Respiratory Syndrome Coronavirus/ or respiratory tract infections/ or bronchitis/ or common cold/ or Pneumonia, Viral/ or (Coronavir* or nCov or Influenza or H1N1 or MERS-COV or flu or Bronchit* or cough or rhinosinusit* or rhinit* or common cold or (respiratory adj2 (infect* or illness or symptom* or acute or virus* or disease*));ti,ab,kw.

#2: exp Vitamin D/ or exp Calcitriol/ or exp Cholecalciferol/ or exp Ergocalciferol/ or exp 25-hydroxyvitamin d 2/ or ("Vitamin d$" or "Vit d" or Calcitriol$ or Cholecalciferol or Ergocalciferol or "25-Hydroxyvitamin D 2").ti,ab,kw

#3: Systematic Review/ or Meta-analysis/ or Systematic Review as Topic/ or Meta-Analysis as Topic/ or Review Literature as Topic/ or (Systematic review or meta analys or metaanaly$).ti,ab,kw

#4: comment/ or letter/ or editorial/

#5: (#1 AND #2 AND #3) NOT #4

2.5. Screening

Titles and abstract screening and full text screening were completed by one reviewer and checked for accuracy by a second reviewer. Similarly, data extraction was completed by a single reviewer and checked for accuracy by a second reviewer. Any discrepancies were resolved by consensus.

2.6. Critical appraisal

The critical appraisal tool for this rapid review was performed using the BMJ Best practice criteria for appraising systematic reviews (https://bestpractice.bmj.com/info/toolkit/learn-ebm/appraising-systematic-reviews/) (Table 2).

3. Results

The initial search resulted in 270 citations [Medline (n = 57), Embase (n = 154), AMED (n = 1), and CINAHL (n = 58)], after duplicates (n = 68) were removed, 202 remained for title and abstract screening. Based on title and abstract review, an additional 138 manuscripts were excluded as irrelevant due methodology (i.e., editorials, commentaries, and/or non-systematic reviews), or broad outcome measures (i.e., not focused on ARTI outcomes). Following abstract review, 36 manuscripts were excluded by full text screening due to methodological limitations not apparent in the abstracts (i.e., narrative reviews), leaving 28 manuscripts for detailed extraction. During detailed data extraction, 5 additional manuscripts were excluded due to inclusion of only observational studies, plus 3 additional exclusions included: an editorial (n = 1), a poster citation (n = 1), and a duplicate republished as a report (n = 1), leaving 20 for the final detailed extraction; see Fig. 1. All citations were imported into Covidence software (Melbourne, Australia) for title and abstract reviews. Full texts were also imported into Covidence for review and data extraction upon finalization of the manuscripts meeting inclusion criteria.

3.1. Critical appraisal

From the appraisal, seven of the 20 reviews met all the requirements. The majority of the studies met most of the criteria in the appraisal tool, however, three reviews were determined to be very poor quality because they met four or fewer of the requirements. The quality of data from these reviews [14–16] in our conclusions and summaries.

3.2. Description of included studies

See Table 1 for a summary of all included studies in the final, detailed review. Of the 20 studies, 13 were systematic reviews and/ or of meta-analysis [16–27], 3 were systematic reviews of randomised controlled trials (RCTs) [28–30], 2 were systematic reviews of various studies [14,31] and 1 was a detailed narrative review of RCTs (and therefore was included), despite low formal quality of design [15]. The 2 systematic reviews with various studies included RCTs, cohort studies, case-control series,
The reviews exclusive to children all used oral administration of vitamin D with 4 reviews reporting on administration of a dose ranging from 300 IU -2000 IU per day [19,21,24,31]. In the 2 reviews exclusive to pregnant women plus children and young men plus children, the dose ranged from 800 IU-2000 IU daily [25,33]. The oral doses for vitamin D in the reviews of all ages varied dramatically from 100 IU to 100,000 IU. See Table 3 for dosage range included in each review.

3.3. Summary of findings

The measurement outcomes from the reviews varied; however, the primary outcome measure evaluated for this review was the incidence of ARTIs (n = 13) [14,15,17,18,20–23,25,27–29,31]. The other main outcome measures included were: the association between vitamin D levels and ARTI risk (5 reviews) [16,26,32,33], pneumonia incidence (3 reviews) [14,19,24], and frequency of hospitalization rates (2 reviews) [14,24]. Several individual reviews reported additional, less specific, outcomes including: frequency of doctor visits, [25], asthma exacerbations [25], incidence of influenza [14], tuberculosis [15] and extra-skeletal disease [30].

Of the 21 reviews, 15 concluded vitamin D was safe and has the potential to reduce the risk of ARTI [15–18,22,23,25,27,29–33]. The other 6 reviews each concluded that there was insufficient evidence to support the protective effect of vitamin D for ARTIs [14,19–21,24,28].

3.4. Reviews supporting a protective effect of vitamin D and ARTI

Autier P., et al. (2017) concluded vitamin D may help to prevent the common upper respiratory tract infections and asthma exacerbation. A 6% risk reduction with vitamin D3 supplementation was identified for clinical RTIs but was of borderline statistical significant; relative risk (RR) = 0.94 [95% CI: 0.88, 1.00] [32]. They hypothesized vitamin D supplementation may exert immunomodulating effects leading to reduced risk of ARTI.

Bergman P., et al. (2013) concluded vitamin D has a protective effect against RTI; odds ratio (OR) = 0.64 [95% CI: 0.49, 0.84]. They also identified that the protective effect was larger in studies that used once-daily dosing compared to bolus doses, OR = 0.51 vs. OR = 0.86 respectively (p < 0.01 for difference) [27].

Charan J., et al. (2012) concluded the overall events of ARI in vitamin D group were 21.7 % (205/943) whereas in placebo group it was 30.1 % (279/925), or an -8.4 % absolute risk reduction in favour of vitamin D. According to their random effects model in children and adults combined, there was significant reduction in the incidence of respiratory tract infection in vitamin D group as compared to placebo group; OR = 0.58 [95% CI: 0.42, 0.81], p < 0.001. In their random effects model for children only (2 studies), vitamin D supplementation reduced the risk of respiratory tract infections significantly (OR = 0.58 [95% CI: 0.42, 0.815], p < 0.001), with identical risk reduction in their fixed effects model (OR = 0.58 [95% CI: 0.42, 0.81], p < 0.001). Limiting analyses to trials in adults only (3 studies), the point estimate for risk favoured vitamin D supplementation but was not statistically significant [22].

Christensen N., et al. (2017) concluded RCTs results and effects from supplementation differed depending on the baseline 25OHD concentration. However, overall the level 1-I moderate to high quality evidence suggested vitamin D has a protective effect for RTI's. (dose >800 IU/day) [25].

Iat K.R., et al. (2017) found that children with lower RTI were found to have significantly lower mean vitamin D levels as compared to controls. There was likewise a correlation between vitamin D levels and incidence and severity of RTI's.
### Table 1
Summary of Included Studies.

| Author          | Year | Design       | Types of Studies included                           | Databases Used                                                                 | Interventions                                                                                       | Participants                                                                                     | Number of Studies | #RCT | Route of Administration (PO, IV) | Total n | Dose                | Placebo or other control | N in intervention and placebo/control | Measure of Outcome | Outcome                                                                 |
|-----------------|------|--------------|---------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------|------|---------------------------|---------|---------------------|--------------------------|----------------------------------------|-------------------|------------------------------------------------------------------------|
| Jolliffe, D     | 2012 | SR RCTs, cohort studies, case-control, cross-sectional | PubMed Vitamin D3                                     | Healthy adults, post-menopausal African American women, recent hip fracture, school children, military conscripts, children with pneumonia, low birth weight infants, children w/ treated asthma, children w/ COPD, healthy children. | 39                                                                                                  | Not stated                                                                                      | 47,360            | 14              | PO 47,360 IU per day | 47,360  | 200 IU, 400 IU, 500 IU, 800 IU, 1200 IU, 2000 IU, 3000 IU, and 1111-6800 IU per day | Placebo Total in RCT = 11,431; Intervention = 5,754, Placebo = 5,677 | ARTI                         | Inconsistent effects on incident ARTI                                      |
| Martineau, A    | 2017 | SR and MA RCT Medline, Embase, Cochrane Central Register of Controlled trials, Web of Science, ClinicalTrials.gov, and Int RCT's D3 and D2 Vitamin D3 | Healthy adults, healthy preschool children, preschool children with pneumonia, military conscripts, children with asthma, low birth weight infants, adults w/ COPD, infants, school children (3rd/4th graders), adults with increased susceptibility to ARTI, children with recurrent acute otitis media, adults with previous colorectal adenoma, healthy older adults, healthy college students, high | 25                                                                                                 | 25                                                                                              | PO 11,321                                                     | Daily dose: 2.5 µg -100 µg Monthly bolus: 0.75 – 5 mg | Placebo Intervention = 4,844; control = 4,548 | Incident ARTI: combined URTI and LRTI | Statistically significant reduction in the proportion of all participants experiencing at least one ARTI; strong protective factor among people with a baseline circulating 25-OHD levels less than 25 nmol/L; however, no significant with levels of 25 or more. Baseline 25-OHD modified the effect on risk of ARTI. Daily or weekly treatment associated with greater degree of protection against ARTI among participants with low and high baseline levels of 25- |
| Author                  | Year | Design | Types of Studies Included | Databases Used                      | Interventions Used       | Participants Included                                                                 | Number of Studies | Route of Administration (PO, IV) | Total n | Intervention Dose | Placebo or other control | N in intervention and placebo/control | Measure of Outcome | Outcome |
|------------------------|------|--------|--------------------------|-------------------------------------|--------------------------|----------------------------------------------------------------------------------------|-------------------|--------------------------------|---------|------------------|----------------------------|--------------------------------------|-------------------|---------|
| Yamshchikov, A         | 2009 | SR     | RCT                      | PubMed and Ovid MEDLINE             | D2 or D3                 | Healthy volunteers receiving flu vaccine; outpatient healthy adults; HIV infected children and teenagers; elderly; healthy menopausal women; children with recent respiratory illness; hemodialysis patients with low PTH levels not otherwise on VitD therapy. | 13 RCT; 7         | PO                            | 4,724   | Wide range: 40 IU daily for 20 years to 100,000 IU of vitamin D3 given bimonthly for 12 months | Placebo = 2,060; | RTI                  | mortality of all-causes and ARTI; Bolus dose of did not offer any protection against ARTI; No effect on risk of serious adverse events or mortality. | Lower rate of reported URI symptoms while receiving 2000 UI D3 per day vs 800 UI D3 per day. Difference in the infection rates between groups no longer significant after 6 months of intervention. |
| Rejnmark, L            | 2017 | SR of MA | RCT                      | PubMed, Embase, and Cochrane Library | D3                      | Studies included newborns, infants, adults, and older adults. 23 of the RCTs studies had respiratory infections as the primary outcomes, while 7 had it as a secondary outcome. Some RCTs investigated the risk of pneumonia, upper or lower RTI, or | 46 studies | PO                            | Not stated | VitD3 dose was administered daily, no range stated | Not stated | RTI                  | 3 out of 7 MA reported beneficial effects on RTI while the rest reported null effects. In 2 RCTs, risk reduced by 40% in pediatric population. The risk significantly reduced in 25 RCTs (OR 0.88, 95% CI (0.81–0.96). Response to a daily or weekly VitD dose showed as a protective effect, but null effect in response |
| Study Authors | Year | Study Design | Database | Vitamin Form | Intervention Details | Control Details | Duration of RTI | Incidence RTI |
|---------------|------|--------------|----------|--------------|---------------------|---------------|----------------|---------------|
| Jayawardena, R. | 2020 | SR RCTs | PubMed, Web of Science, and SciVerse Scopus | Vitamin D, any form | 43 re: VitD PO, IV 26803 | Placebo/ intervention = 13947 | First/only episode of radiologically confirmed pneumonia | Incidence wintertime URTI | Significantly lesser URTI in elderly participants |
| Jat, K.R et al. | 2016 | SR and MA RCTs | PubMed, Embase, and Cochrane | Vitamin D, any form | PO 3,946 | Placebo (2) Intervention = 1991 | First/only episode of confirmed pneumonia | No difference in incidence of the first/only episode of pneumonia. | Adverse events in 2 children (single episode of vomiting and another had diarrhea for 2 days). |
| Vuichard Gysin, D. | 2016 | SR and MA RCTs | Medline, EMBASE, CENTRAL, and CINAHL | Vitamin D, any form | 15 PO 7053 | Placebo/ control = 3844 | Incidence RTI | –6% risk lower in the vitamin D group (not statistically significant) |

**Exacerbations** in patients with asthma or COPD.

Healthy adults and children, HCV and HBV patients, elderly, children with HBV, male smokers (immunity to influenza-like viral infections).

Infants aged 1-11 mo, Children between 2 mo-5yrs with a diagnosis of severe pneumonia, School-aged children from 3rd-4th grade classrooms, and Children with pneumonia and severe pneumonia (LRTI in children).
| Author          | Year | Design | Types of Studies included | Databases Used                                                                 | Intervention | Participants | Number of Studies | Route of Administration (PO, IV) | Total n | Dose               | Placebo or other control | N in intervention and placebo/control | Measure of Outcome                  | Outcome                                                                 |
|-----------------|------|--------|---------------------------|--------------------------------------------------------------------------------|--------------|--------------|------------------|-----------------------------------|---------|--------------------|-------------------------------|--------------------------------------|-----------------------------------|------------------------------------------------------------------------|
| Xiao L et al    | 2015 | SR with MA | RCT                        | Medline, EMBASE, Cochrane Central Register of Controlled Trials Pubmed, Cochrane clinical trial register, google scholar | Vitamin D, any form | Younger than 18 years old | 4 RCT for ARTI            | PO                                | 3,771   | Daily: 300–1200 IU | Placebo                        | Not reported                        | Incidence of ARI                 | No significant decrease: RR = 0.79 [95% CI: 0.55–1.13]                |
| Charan J et al  | 2012 | SR with MA | RCT                        | Medline, EMBASE, Cochrane Central Register of Controlled Trials Pubmed, Cochrane clinical trial register, google scholar | Vitamin D, any form | Children and adults       | 5 RCT                  | PO                                | Not stated | 400–2000 IU/day | Placebo                        | Unclear                             | Frequency of acute respiratory infection | ~8.4% risk reduction in overall ARI in adults and children combined, and in subgroup of children only, but not subgroup of adults only |
| Marzetke, F.    | 2020 | SR      | RCTs                      | PubMed, Cochrane Reviews Library                                        | Vitamin D, any form | 14 just on children, 3 both children and adults | 18                     | PO                                | N/A - Mendelian RCT alone = 146,761 | Ranged between 10 μg - 10,000 μg (bolus dose) | Control | N/A                | ARTI                           | Beneficial effect in primary prevention No significant treatment effect measured Increased incidence or severity if deficient in Vitamin D Reduced risk: Adjusted OR = 0.88 [95% CI: 0.81 to 0.96] Protective effects seen in those receiving daily or weekly doses. Protective effects were stronger in those with baseline 25-OH D levels <25 nmol/L (adjusted odds ratio = 0.30 [95% CI: 0.17 to 0.53] Did not influence risk of serious adverse event (adjusted odds ratio 0.98, 0.80–1.20, P = 0.83). |
| Larkin, A.      | 2013 | SR      | CS: 6, CCS: 2, RCS: 1, CSS: 1, RCS: 2 | Medline, CI-NAHL, Cochrane Library | Vitamin D, any form | Children age 0–5 with and without ALRTI | 2                     | PO                                | 3499 (from the 2 RCTs in review) | 2.5 mg | Intervention = 1748; Placebo = 1751 | ARTI                           | Incident ARTI                     | ALRTI                              | Increased incidence or severity of acute respiratory infection in those receiving daily or weekly doses. Protective effects were stronger in those with baseline 25-OH D levels <25 nmol/L (adjusted odds ratio = 0.30 [95% CI: 0.17 to 0.53] Did not influence risk of serious adverse event (adjusted odds ratio 0.98, 0.80–1.20, P = 0.83). |
| Martineau, A.R. | 2016 | SR with MA | RCT                        | Medline, EMBASE, Cochrane Central Register of Control Trials (CENTRAL), Web of Science, ClinicalTrials.gov, and International Standard RCT Number (ISRCTN) | Vitamin D, any form | All ages                   | 25                    | PO                                | 11,321  | 10 μg - 100 μg | Control                        | Intervention = 5,904; Placebo = 5,417 | Incident ARTI                     | Protective effects were stronger in those with baseline 25-OH D levels <25 nmol/L (adjusted odds ratio = 0.30 [95% CI: 0.17 to 0.53] Did not influence risk of serious adverse event (adjusted odds ratio 0.98, 0.80–1.20, P = 0.83). |
| Name                  | Year | Research Design | PubMed and Google Scholar | Vitamin D, any form | Study Count | PO | Placebo | Incidence | Intervention | Placebo | Outcome | Evidence Quality |
|-----------------------|------|-----------------|----------------------------|---------------------|-------------|----|----------|------------|--------------|----------|----------|----------------|
| Zittermann, A. 2015   | Narrative Review | PubMed and Google Scholar | Vitamin D, any form | 6 studies for treatment of TB (tuberculosis), while 16 studies examined prevention of respiratory tract infection in healthy recruits and/or amongst patients | 22 | 16 PO | 8,705 | Daily: 10 μg - 20 μg | Control N/A | Incident ARTI | Significant risk reduction by vitamin D supplements [OR = 0.65 [95% CI: 0.50–0.85] Daily administration more effective than high-dose bolus administration (OR = 0.48 [95% CI: 0.30–0.77] vs. OR = 0.87 [95% CI: 0.67–1.14] and more effective in deficiency. |
| Yakoob, M.Y. 2016     | SR RCT and MA | Cochrane Infectious Diseases Group (CIDG) Specialized Register; the Cochrane Central Register for Controlled Trials (CENTRAL); MEDLINE (PubMed); EMBASE, LILACS, WHO International Clinical Trials Registry, ClinicalTrials.gov, ESRCTN Registry | Vitamin D, any form | 3198 children under 5 years of age (conducted in Afghanistan, Spain, and the USA) | 4 | 4 PO | 3198 | 10 μg - 2.50 mg | Control | Pneumonia incidence (n = 2) | No effect on the occurrence of the first or only episode of pneumonia; or on children with pneumonia, irrespective of whether this had been confirmed by hospital tests (moderate quality evidence). |
| Christensen, N. 2017  | SR RCTs, MA and observational studies | Pubmed, Embase and the Cochrane | Vitamin D, any form | Pregnant women and children with 5 years old or younger | 22 | 4 PO | RTCs = 1944 | Daily 2,000 IU, 800 IU | Placebo Not specified | Wheeze RTI | Protective effect on infant wheeze Inconclusive on RTI Favorable doses higher than 800 IU/d. Supplementation of VitD in healthy population does not prevent RTI. A serum level of at least 10 nmol/L higher than the mean basic serum level concentration appears to be protective. Vitamin D may be |
| Mao, S. 2013         | MA   | MA of RCTs | Vitamin D, any form | "Healthy patients" | 7 | 7 PO | 4827 | 300 to 6,800 IU/day | Placebo | Intervention: 2,440 Placebo:2,387 | Incident ARTI | Serum VitD levels |
| Moroti, R. 2012      | SR RCTs | Pubmed | Vitamin D, any form | Children and young men | 10 | 10 PO | 3349 | 800-2000 IU | Placebo | 625/715 | Serum VitD levels |
Jayawarden R., et al. (2020) concluded serum status is likely to be a predictor of immune responses to vitamin D supplementation, and ARTI may be significantly lower in vitamin D groups among elderly participants in long term care facilities, but concluded most trails demonstrated no overall differences in the incidence of upper respiratory tract infections between vitamin D and controls, likely due to participant and dosing heterogeneity [29].

Larkin A., et al. (2013) results showed that a vitamin D deficiency was notably prevalent among both mothers and infants and deficiency was associated with an increased risk of ARTIs [31].

Maretzke F., et al. (2020) concluded observational data supported primary prevention, with a significant inverse association between vitamin D status and risk of ARTIs, with RCTs supporting similar conclusions [30].

Martineau A., et al. (2016) found that vitamin D supplementation reduced risk of ARTIs among all participants (adjusted OR = 0.88 [95% CI: 0.81, 0.96]; p for heterogeneity <0.001). Protective effects seen in those receiving daily or weekly vitamin D without additional bolus doses. Among those receiving daily or weekly vitamin D, protective effects were stronger in those with baseline 25-OHD levels <25 nmol/L (adjusted OR = 0.30 [95% CI: 0.17, 0.53]) compared to those with baseline 25-OHD levels ≥25 nmol/L (adjusted OR = 0.81, [95% CI: 0.60, 0.95]) p for interaction=0.006. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted OR = 0.98 [95% CI: 0.80, 1.20], p = 0.83) [23].

Martineau A., et al. (2017) concluded vitamin D supplementation resulted in statistically significant reduction in the proportion of participants experiencing at least one ARTI. Vitamin D supplementation was a strong protective factor among people with a baseline circulating 25-OHD <25 nmol/L; however, no significant effects among those with levels of ≥25 nmol/L. Baseline vitamin D status and dosing frequency independently modified the effect of Vitamin D supplementation on risk of ARTI. Daily or weekly vitamin D treatment was associated with a greater degree of protection against ARTI among participants with low baseline levels of 25-OHD. Bolus dose of Vitamin D did not appear to offer protection against ARTI. Vitamin D did not influence the risk of serious adverse events or mortality due to any cause [17].

Moroti R., et al. (2012) concluded 25-OHD at least 10 nmol/L higher than the mean concentration offered protection against ARTI, and vitamin D may be an effective adjuvant in the anti-infective therapy [33].

Reinehr T., et al. (2018) concluded vitamin D may potentially reduce the risk of influenza, improve asthma and reduce exacerbation of bronchiol spasms, but had no impact on severity of bronchiol spasms [16].

Rejnmark L., et al. (2017) concluded 3 out of 7 meta-analysis reported beneficial effects of Vitamin D supplementation on RTI while the rest reported null effects. In 2 RCTs, vitamin D supplementation significantly reduced the risk of RTI by 40% in paediatric population. The risk of ARTI was significantly reduced in 25 RCTs in the general population (OR = 0.88 [95% CI: 0.81, 0.96]. Response to a daily or weekly vitamin D dose showed as a protective effects, but null effect in response to one or more bolus doses [18].

Zittermann A., et al. (2015) concluded vitamin D deficiency increased the risk of ARTI but there was no evidence vitamin D lowered the risk of other common infections. They also recommended supplementation with vitamin D (dose 600-2,000 IU/day) for prophylaxis, particularly in winter, due to the high vitamin D deficiency found in the European population [15].
### Table 2
Systematic review quality evaluation.

| Author          | 1: Comprehensive and reproducible search? | 2: Clearly focussed question? | 3: Inclusion/exclusion criteria clearly stated? | 4: Are primary RCT data reported? | 5: Methodological quality assessment? | 6: Meta: Are primary studies combined appropriately? | 7: Meta: Combined statistics reported? | 8: Meta: Report absolute numbers and summary stats? | 9: Is heterogeneity discussed? | 10: Is relevance/significance discussed? | Total out of 10 |
|-----------------|------------------------------------------|-------------------------------|-----------------------------------------------|----------------------------------|---------------------------------------|---------------------------------------------|------------------------------------|-----------------------------------------|----------------|----------------------------------------|------------------|
| Jolliffe, D.    | ?                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | ?                                  | ?                                  | +                          | 4                          |                  |
| Martineau, A    | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | ?                                  | +                                    | +                          | 9                          |                  |
| Yamshchikov, A  | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | ?                                  | +                                    | +                          | 6                          |                  |
| Rejnmark, L     | ?                                        | +                             | ?                                             | ?                                | ?                                    | ?                                           | ?                                  | +                                    | –                          | 5                          |                  |
| Jayawardena, R. | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | ?                                  | +                                    | 7                          |                |                  |
| Jat, K.R et al. | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | ?                                  | +                                    | +                          | 10                         |                  |
| VuichardGysin,  | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | ?                                  | +                                    | +                          | 10                         |                  |
| D. Xia, L et al.| +                                        | +                             | –                                             | +                                | +                                    | +                                           | +                                  | +                                    | 9                          |                          |                  |
| Charan J et al. | +                                        | +                             | +                                             | –                                | +                                    | +                                           | +                                  | +                                    | 9                          |                          |                  |
| Marzetke, F.    | +                                        | +                             | –                                             | +                                | ?                                    | ?                                           | ?                                  | +                                    | +                          | 6                          |                  |
| Larkin, A.      | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | ?                                  | –                                    | +                          | 6                          |                  |
| Martineau, A.R. | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | ?                                  | –                                    | +                          | 10                         |                  |
| Zittermann, A.  | –                                        | +                             | –                                             | +                                | ?                                    | ?                                           | +                                  | +                                    | +                          | 4                          |                  |
| Yakoob, M.Y.    | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | +                                  | +                                    | +                          | 10                         |                  |
| Christensen, N. | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | +                                  | +                                    | +                          | 10                         |                  |
| Jat KR          | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | +                                  | +                                    | +                          | 9                          |                  |
| Mao, S.         | +                                        | +                             | +                                             | ?                                | ?                                    | ?                                           | +                                  | +                                    | +                          | 10                         |                  |
| Morot, R.       | –                                        | –                             | –                                             | +                                | +                                    | ?                                           | +                                  | ?                                    | –                          | 4                          |                  |
| Reinehr, T.     | –                                        | –                             | –                                             | –                                | –                                    | –                                           | –                                  | –                                    | +                          | 1                |                  |
| Autier 2017     | +                                        | +                             | +                                             | –                                | +                                    | +                                           | –                                  | +                                    | –                          | 7                          |                  |
| Bergman 2013    | +                                        | +                             | +                                             | +                                | +                                    | +                                           | +                                  | +                                    | +                          | 10                         |                  |

Legend: Yes (+); No (-); Can’t Tell (?).

### Table 3
Dosing Ranges in Reviewed Manuscripts.

| Author/Year | Dose (IU) | 40 | 200 | 300 | 400 | 500 | 800 | 1,000 | 1,500 | 2,000 | 3,000 | 4,000+ | 10,000+ | 100,000+ |
|-------------|-----------|----|-----|-----|-----|-----|-----|-------|-------|-------|-------|--------|---------|---------|
| Yamshchikov2009 | X / B      | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Charan2012    |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Jolliffe2012  |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Morot2012     |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Bergman2013   |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Larkin2013    |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Mao2013       |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Xiao2015      |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Zittermann2015|           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Jat2016       |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Martineau2016 |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Vuichard Gysin2016 |     | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Yakoob2016    |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Autier2017    |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Christensen2017|           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Martineau/Rejnmark2017 | X / B/IV | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Reinehr2018   |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Jayawardena2020|          | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |
| Marzetke2020  |           | X  | X   | X   |  X  | X   | X   | X     | X     | X     | X     |  X     | X       | B       |

U/S = unspecified; B = bolus dosing; IV = intravenous administration; X indicates the review identifies the use of this dose in the studies they reviewed.

### 3.5. Reviews supporting null effects of vitamin D and ARTI

Jolliffe D., et al. (2013) concluded observational studies found a statistical significance between vitamin D deficiency and increased risk of ARTIs. However, they also identified conflicting RCTs, and therefore concluded vitamin D supplementation did not conclusively demonstrate protection against ARTIs [14].

Mao et al. (2013) reported a pooled RR = 0.98 [95% CI: 0.93–1.03], p = 0.45 of ARTI from vitamin D supplementation and, therefore, concluded the routine use of vitamin D supplementation cannot be recommended for ARTI prevention in healthy populations healthy populations [26].

Xiao L, et al. (2015) reported no significant decreases in the incidence of ARTI (RR = 0.79 [95% CI: 0.55, 1.13]), all-cause mortality (RR = 1.18 [95% CI: 0.71–1.94]), or the rate of hospitalization due to RTI’s in healthy children (RR = 0.95 [95% CI: 0.72, 1.26]) from vitamin D supplementation [21].

Yakoob M., et al. (2016) concluded, based on moderate quality evidence, there was no effect of vitamin D supplementation on the occurrence of pneumonia; nor any effect in children with
pneumonia. No conclusions could be made regarding whether vitamin D influenced hospital admissions as there was only one small study assessing this outcome, which had very low quality [24]. The types or causes of pneumonia were not specifically evaluated.

Vuichard Gysin et al. (2016) reported a pooled risk of ARTI 6% lower in the vitamin D group compared to non-treatment group, a 10 % lower risk of lab-confirmed ARTI among vitamin D group, a marginal mean reduction in symptom duration, and lower symptom severity in vitamin D groups; however the point estimates for these risk reductions did not reach statistically significance [20].

Yamshchikov A., et al. (2009) reported no difference in frequency, severity, or duration of upper respiratory tract infections (URTI), but statistical trends favoured vitamin D in all outcomes, including a lower frequency of wintertime URTI symptoms in intervention group, and a lower frequency of reported URTI symptoms while receiving 2,000 IU vitamin D3/ day compared to 800 IU vitamin D3/day. However, the difference in infection rates between groups was no longer significant after 6 months of intervention. There was also no difference in the change in CD4 count or viral load between groups [28].

4. Clinical significance

Despite several positive systematic reviews and meta-analyses, the available experimental evidence related to the effects of vitamin D on acute respiratory tract infection (ARTI) is plagued with heterogeneity and mixed quality, and therefore is insufficient to recommend vitamin D supplementation to the general population as a protective agent against ARTI. However, based on the evidence identified in this rapid review (including a high margin of clinical safety), combined with strong mechanistic rationale, the following recommendations can be made for those at risk of ARTI: 1. vitamin D status should be tested for those at risk of ARTI; 2. patients identified with deficiency or insufficiency should be supplemented with vitamin D until their status is normalized; and 3. daily dosing of vitamin D3 is preferred to achieve serum concentrations >50 nmol/L in a timely manner. Clinical trials support vitamin D doses of 800 IU/day up to 10,000 IU/day [34], with 1,000–2,000 IU/day being a common dosing strategy in clinical trials, and potentially more effective then lower daily or bolus dosing strategies.

Disclaimer

This article should not replace individual clinical judgement. The views expressed in this rapid review are the views of the authors and not necessarily from the host institutions. The views are not a substitute for professional medical advice.

References

[1] J.M. Lemire, et al., 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells, J. Clin. Invest. 74 (2) (1984) 657–661.
[2] S. Chen, et al., Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation, J. Immunol. 179 (3) (2007) 1634–1647.
[3] B.D. Mahon, et al., The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells, J. Cell. Biochem. 89 (5) (2003) 922–932.
[4] F. Baee, et al., Vitamin D: moderator of the immune system, Curr. Opin. Pharmacol. 10 (4) (2010) 482–496.
[5] M. Hewison, An update on vitamin D and human immunity, Clin. Endocrinol. (Oxf.) 76 (3) (2012) 315–325.
[6] M.T. Cantorna, Mechanisms underlying the effect of vitamin D on the immune system, Proc. Nutr. Soc. 69 (3) (2010) 286–289.
[7] F. Baee, et al., The vitamin D analog, TX527, promotes a human CD4 +CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation, J. Immunol. 186 (1) (2011) 1372–142.
[8] J.M. Lemire, et al., Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions, J. Nutr. 125 (6 Suppl) (1995) 1704S–1708S.
[9] T.L. Van Belle, C. Gysemans, C. Mathieu, Vitamin D in autoimmune, infectious and allergic diseases: a vital player? Best Pract. Res. Clin. Endocrinol. Metab. 25 (4) (2011) 617–632.
[10] M.T. Palmer, et al., Lineage-specific effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on the development of effector CD4+ T cells, J. Biol. Chem. 286 (2) (2011) 997–1004.
[11] A. Boonstra, et al., 1,25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells, J. Immunol. 167 (9) (2001) 4974–4980.
[12] D.J. Berry, et al., Vitamin D status has a linear association with seasonal infections and lung function in British adults, Br. J. Nutr. 106 (9) (2011) 1433–1440.
[13] D.J. Moulezn, et al., Vitamin D status and acute respiratory infection: cross sectional results from the United States National Health and Nutrition Examination Survey, 2001-2006, Nutrients 7 (3) (2015) 1933–1944.
[14] O.A. Jolliffe, A.R. Martineau, C.J. Griffiths, Vitamin D in the prevention of acute respiratory infection: a systematic review of clinical studies, Thorax 67 (SUPPL. 2) (2012) A71–A72.
[15] A. Zittermann, S. Pilz, W. Marz, Vitamin D and susceptibility to infection, Aktuelle Ernahrungsmedizin 40 (4) (2015) 240–246.
[16] T. Reuweg, et al., Vitamin D supplementation beyond the second year of life: Joint statement of the Nutrition Committee of the German Society for Pediatric and Adolescent Medicine (DGKJ) and the German Society for Pediatric Endocrinology and Diabetology (DGKD), Monatschrift fur Kinderheilkunde 166 (9) (2018) 814–822.
[17] A.R. Martineau, et al., Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data, BMJ (Clin. Res. Ed.) 356 (2017) e5833 8900488, bmj, 1010908666.
[18] L. Bjorndal, et al., Non-skeletal health effects of vitamin D supplementation: a systematic review on findings from meta-analyses summarizing trial data, PLoS One 12 (7) (2017) e0180512.
[19] R.K. Jat, Vitamin D and lower respiratory tract infection in children: a systematic review and meta-analysis of randomized controlled trials, Clin. Pulm. Med. 23 (4) (2016) 157–162.
[20] D. Vuichard Gysin, et al., Effect of vitamin D3 supplementation on respiratory tract infections in healthy individuals: a systematic review and meta–analysis of randomized controlled trials, PLoS One 11 (9) (2016) e0162996.
[21] L. Xiao, et al., Vitamin D supplementation for the prevention of childhood acute respiratory infections: a systematic review of randomised controlled trials, Br. J. Nutr. 114 (7) (2015) 1026–1034.
[22] J. Charan, et al., Vitamin D for prevention of respiratory tract infections: a systematic review and meta-analysis, J. Pharmacol. Pharmacother. 3 (4) (2012) 300–303.
[23] A.R. Martineau, et al., Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of individual participant data, Thorax 71 (Supplement 3) (2016) A60–A61.
[24] M.Y. Yakooob, et al., Vitamin D supplementation for preventing infections in children under five years of age, Cochrane Database Syst. Rev. 2016 (11) (2016) CD008824.
[25] N. Christensen, et al., Infant respiratory tract infections or wheeze and maternal vitamin D in pregnancy: a systematic review, Pediatr. Infect. Dis. J. 36 (4) (2017) 384–391.
[26] S. Mao, S. Huang, Vitamin D supplementation and risk of respiratory tract infections: a meta–analysis of randomized controlled trials, Scand. J. Infect. Dis. 45 (9) (2013) 696–702.
[27] P. Bergman, et al., Vitamin D and respiratory tract infections: a systematic review and meta–analysis of randomized controlled trials, PLoS One 8 (6) (2013) e65835.
[28] A.V. Yamshchikov, et al., Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials, Endocrine Pract. 15 (5) (2009) 438–449.
[29] R. Jayawardena, et al., Enhancing immunity in viral infections, with special emphasis on COVID-19: a review, Diabetes Metab. Syndr. Clin. Res. Rev. 14 (4) (2020) 367–382.
[30] F. Marete et al., Role of vitamin D in preventing and treating selected extraskelatal diseases-an umbrella review, Nutrients 12 (4) (2020) 969.
[31] A. Larkin, J. Lasseter, Vitamin D deficiency and pediatric respiratory infection. Comnat. Nurs. Res. 46 (2013) p. 683-683.
[32] P. Auter, et al., Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomized trials, Lancet Diabetes Endocrinol. 5 (12) (2017) 986–1004.
[33] R. Morozi, et al., Vitamin D an antimicrobial weapon against acute respiratory tract infections, A systematic review (2006- March 2011), Farmacia 60 (2) (2012) 159–167.
[34] D.M. Trush, et al., Impact of vitamin D3 dietary supplement matrix on clinical response, J. Clin. Endocrinol. Metab. 99 (8) (2014) 2720–2728.